scholarly article | Q13442814 |
P50 | author | Janne Koskimäki | Q85280839 |
Romuald Girard | Q87294525 | ||
Kelly Flemming | Q89357428 | ||
Sean P Polster | Q90469109 | ||
P2093 | author name string | Ying Cao | |
Nicholas Hobson | |||
Helen Kim | |||
Karen Lane | |||
Richard E Thompson | |||
Jennifer J Majersik | |||
Timothy Carroll | |||
Leslie Morrison | |||
Agnieszka Stadnik | |||
Daniel Hanley | |||
Issam A Awad | |||
Nichol McBee | |||
Robert Shenkar | |||
Hussein A Zeineddine | |||
James Koenig | |||
Joseph Zabramski | |||
P2860 | cites work | Loss of CCM3 impairs DLL4-Notch signalling: implication in endothelial angiogenesis and in inherited cerebral cavernous malformations | Q24314844 |
Cerebral cavernous malformation protein CCM1 inhibits sprouting angiogenesis by activating DELTA-NOTCH signaling | Q24338286 | ||
Exceptional aggressiveness of cerebral cavernous malformation disease associated with PDCD10 mutations | Q30389638 | ||
Dynamic contrast-enhanced MRI evaluation of cerebral cavernous malformations | Q30712120 | ||
Prospective, population-based detection of intracranial vascular malformations in adults: the Scottish Intracranial Vascular Malformation Study (SIVMS). | Q30786918 | ||
Clinical course of untreated cerebral cavernous malformations: a meta-analysis of individual patient data. | Q31031466 | ||
Prevalence, Clinical Management, and Natural Course of Incidental Findings on Brain MR Images: The Population-based Rotterdam Scan Study | Q31110242 | ||
Vascular permeability and iron deposition biomarkers in longitudinal follow-up of cerebral cavernous malformations. | Q31119793 | ||
Cerebral cavernous malformation: new molecular and clinical insights | Q33342264 | ||
Hemorrhage from cavernous malformations of the brain: definition and reporting standards. Angioma Alliance Scientific Advisory Board | Q33381502 | ||
Lesions from patients with sporadic cerebral cavernous malformations harbor somatic mutations in the CCM genes: evidence for a common biochemical pathway for CCM pathogenesis. | Q33920720 | ||
Outcome after surgical or conservative management of cerebral cavernous malformations | Q34079287 | ||
KRIT1 protein depletion modifies endothelial cell behavior via increased vascular endothelial growth factor (VEGF) signaling | Q34552843 | ||
Evaluation of iron content in human cerebral cavernous malformation using quantitative susceptibility mapping | Q34626246 | ||
Walking after stroke. Measurement and recovery over the first 3 months | Q69004002 | ||
Pathological heterogeneity of angiographically occult vascular malformations of the brain | Q72586272 | ||
Spectrum of genotype and clinical manifestations in cerebral cavernous malformations | Q79718991 | ||
Association between disability measures and short-term health care costs following intracerebral hemorrhage | Q81771623 | ||
A randomized, controlled trial of oral propranolol in infantile hemangioma. | Q34668015 | ||
Dynamic permeability and quantitative susceptibility: related imaging biomarkers in cerebral cavernous malformations | Q35151828 | ||
Strategy for identifying repurposed drugs for the treatment of cerebral cavernous malformation. | Q35167117 | ||
Immune complex formation and in situ B-cell clonal expansion in human cerebral cavernous malformations. | Q35174618 | ||
The neurology quality-of-life measurement initiative | Q35343088 | ||
Sensitivity of patients with familial cerebral cavernous malformations to therapeutic radiation | Q35624537 | ||
Fasudil decreases lesion burden in a murine model of cerebral cavernous malformation disease | Q35693325 | ||
Untreated clinical course of cerebral cavernous malformations: a prospective, population-based cohort study | Q35764796 | ||
Sulindac metabolites decrease cerebrovascular malformations in CCM3-knockout mice | Q35845857 | ||
Vascular permeability in cerebral cavernous malformations. | Q36267403 | ||
Defective autophagy is a key feature of cerebral cavernous malformations | Q36278717 | ||
Health related quality of life of stroke survivors: experience of a stroke unit | Q36736716 | ||
Cerebral cavernous malformations: natural history and prognosis after clinical deterioration with or without hemorrhage | Q36875970 | ||
Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signalling | Q36892606 | ||
Peripheral plasma vitamin D and non-HDL cholesterol reflect the severity of cerebral cavernous malformation disease | Q37050968 | ||
Biallelic somatic and germline mutations in cerebral cavernous malformations (CCMs): evidence for a two-hit mechanism of CCM pathogenesis | Q37092450 | ||
Quantitative Susceptibility Mapping in Cerebral Cavernous Malformations: Clinical Correlations. | Q37099099 | ||
Radiosurgery for angiographically occult vascular malformations | Q37466664 | ||
Rehabilitation after stroke | Q37969232 | ||
Synopsis of Guidelines for the Clinical Management of Cerebral Cavernous Malformations: Consensus Recommendations Based on Systematic Literature Review by the Angioma Alliance Scientific Advisory Board Clinical Experts Panel | Q38848129 | ||
KRIT1 loss of function causes a ROS-dependent upregulation of c-Jun | Q38873324 | ||
B-Cell Depletion Reduces the Maturation of Cerebral Cavernous Malformations in Murine Models. | Q38880171 | ||
Evaluation of the bioactive properties of avenanthramide analogs produced in recombinant yeast. | Q38914490 | ||
Clinical determinants of long-term quality of life after stroke | Q39790682 | ||
Solitary Sporadic Cerebral Cavernous Malformations: Risk Factors of First or Recurrent Symptomatic Hemorrhage and Associated Functional Impairment | Q40811124 | ||
Natural history of intracranial cavernous malformations | Q42486712 | ||
EndMT contributes to the onset and progression of cerebral cavernous malformations | Q45333641 | ||
Platinum nanozymes recover cellular ROS homeostasis in an oxidative stress-mediated disease model | Q46604327 | ||
Quality of Life After Surgery for Cerebral Cavernoma: Brainstem Versus Nonbrainstem Location | Q47672578 | ||
Factors predisposing to clinical disability in patients with cavernous malformations of the brain | Q48290193 | ||
A comparison of the clinical profile of cavernous malformations with and without associated venous malformations | Q48302819 | ||
RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations. | Q48419319 | ||
Natural history of the cavernous angioma | Q48627465 | ||
Quality of life after brainstem cavernoma surgery in 71 patients. | Q48686644 | ||
Endothelial Cells Lining Sporadic Cerebral Cavernous Malformation Cavernomas Undergo Endothelial-to-Mesenchymal Transition | Q48931961 | ||
Which is more valid for stroke patients: generic or stroke-specific quality of life measures? | Q48959683 | ||
Hemorrhage risks and functional outcomes of untreated brainstem cavernous malformations. | Q50666265 | ||
Propranolol Treatment of Cavernous Malformations with Symptomatic Hemorrhage. | Q50959104 | ||
Health-related quality of life among long-term survivors of stroke : results from the Auckland Stroke Study, 1991-1992. | Q51977778 | ||
Measuring quality of life in a way that is meaningful to stroke patients. | Q53537651 | ||
Biallelic somatic and germ line CCM1 truncating mutations in a cerebral cavernous malformation lesion. | Q54679968 | ||
P433 | issue | 4 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 954-964 | |
P577 | publication date | 2018-04-11 | |
P1433 | published in | Neurosurgery | Q7002693 |
P1476 | title | Trial Readiness in Cavernous Angiomas With Symptomatic Hemorrhage (CASH). | |
P478 | volume | 84 |
Q92884386 | Biomarkers of cavernous angioma with symptomatic hemorrhage |
Q90085339 | Phantom validation of quantitative susceptibility and dynamic contrast-enhanced permeability MR sequences across instruments and sites |
Q90668506 | Predictors of Initial Presentation with Hemorrhage in Patients with Cavernous Malformations |
Q92317498 | Symptomatic Cavernous Malformation Presenting with Seizure without Hemorrhage: Analysis of Factors Influencing Clinical Presentation |
Search more.